Jardiance® reduced risk of cardiovascular death in people with type 2 diabetes and established CV disease* independent of background blood sugar control
New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) reduced the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular (CV) disease*, independent of blood sugar control at the start of the study.1 A reduction in cardiovascular death was also seen when Jardiance® was added to common first and second-line diabetes medications, such as metformin or sulphonylurea.2,3 These results from post-hoc analyses were presented by Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912005928/en/
“Now that we have a new option for reducing the risk of cardiovascular death among people with type 2 diabetes, we are striving to better understand if there are differences in how patients can benefit,” said Prof. Silvio Inzucchi, Section of Endocrinology, Yale School of Medicine, New Haven, USA, who presented the data today. “These new analyses of the EMPA-REG OUTCOME® trial showed empagliflozin was effective in reducing the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, no matter what the blood sugar levels at the start of the study were or if empagliflozin was added to commonly used oral blood sugar lowering treatments.”
In all four blood sugar level groups at study start (HbA1c levels of <7.0%, 7.0% to <8.0%, 8.0% to <9.0% and ≥9.0%), patients receiving Jardiance® demonstrated a reduction in the risk of cardiovascular death compared with placebo. This was consistent with the risk reduction seen in the overall trial population* and seen irrespective of whether blood sugar control was improved following introduction of the study treatment (as measured by a decrease in HbA1c level of ≥ 0.5% at week 12).1
Additional post-hoc analyses showed that when Jardiance® was added to metformin or sulphonylurea, the reduction of cardiovascular death compared to placebo was consistent with the overall trial population*. These analyses also showed the proportion of patients with hypoglycaemic adverse events were similar between the placebo and Jardiance® groups in the EMPA-REG OUTCOME® trial.2,3
The 7,020-patient EMPA-REG OUTCOME® trial results, first published in the New England Journal of Medicine in 2015, had shown that Jardiance® reduced the relative risk of cardiovascular death by 38 percent compared to placebo in patients with type 2 diabetes and established cardiovascular disease* on top of standard of care (including glucose-lowering agents and cardiovascular drugs). The overall safety profile of Jardiance® was consistent with that of previous clinical trials and current label information.4,5
“Cardiovascular disease is the primary cause of death in people with type 2 diabetes," said David Kendall, M.D., Distinguished Medical Fellow, Lilly Diabetes. “The results presented at EASD provide further evidence of the benefit empagliflozin can provide to patients with different background blood sugar control.”
“The Boehringer Ingelheim and Eli Lilly Diabetes Alliance leads the paradigm shift in the treatment of people with type 2 diabetes”, said Dr Georg van Husen, Corporate Senior Vice President, Head of the Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “The EMPA-REG OUTCOME® trial showed a remarkable reduction in CV death by 38% and the new data indicates that this effect is independent of the blood sugar control."
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.
Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body (i.e. sodium) and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). The glucosuria, natriuresis and osmotic diuresis observed with empagliflozin may contribute to the improvement in cardiovascular outcomes.5
Empagliflozin is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).
About EMPA-REG OUTCOME
EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 people from 42 countries with type 2 diabetes at high risk for cardiovascular events.
The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.
Over a median of 3.1 years, Jardiance® significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. The risk of CV death was reduced by 38 percent, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. The overall safety profile of empagliflozin was consistent with that of previous trials.
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Jardiance and its safety profile, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that Jardiance will receive additional regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/EASD-2017
*Adult patients with type 2 diabetes and coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke
Dr Petra Kienle
Product Communication Manager
Phone: +49 (6132) 77 143877
Phone: +1 (317) 478 5423
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
düber Technologies Inc. Secures Funding for 15 Distribution Centers with $50 Million Agreement with Vacone Real Estate26.9.2017 23:59 | Tiedote
düber Technologies Inc., a software-as-a-service (SaaS) provider serving the cannabis industry, today announced it has signed a $50 million funding agreement with Vacone Real Estate for the acquisition, fit out and master lease for 15 cannabis distribution centers in Washington, Oregon, California, Nevada and Arizona. The deal will allow düber to expand operations to include 400,000 square feet of distribution space that will form the basis of the düber unified distribution technology platform. “At düber, we see an unmet market opportunity for cannabis producers, processors and retailers in key parts of the country,” said Glenn Ballman, founder of düber. “This expansion will allow us to serve our distribution and courier partners while continuing to expand our integrated, omnichannel, real-time platform to partners and consumers in key markets in the cannabis industry
Piraeus Bank Comments on Bank of Greece Audit26.9.2017 19:20 | Tiedote
In response to a query by the Hellenic Capital Markets Committee, Piraeus Bank notifies the investment community that, on 19 September 2017 and following our prior announcement regarding the same matter, we received a draft report for an audit conducted by the Bank of Greece in the course of an Annual Audit Plan. The audit commenced in February 2017, was concluded in July 2017, and focused on a review of the Bank’s procedures for the implementation of the regulatory framework, as well as risk management procedures and special credit issues. Piraeus Bank cooperated fully and constructively with the Bank of Greece during the audit process. Piraeus Bank will respond to the Bank of Greece within a specific timeline and the final report from the Bank of Greece is expected to follow. Piraeus Bank considers that the historic issues covered by the Bank o
Oxera Releases New Analysis on Europe’s Aviation Market, Revealing Increased Competition between Airports26.9.2017 19:13 | Tiedote
Oxera Consulting LLP has revisited the subject of airport competition in Europe, conducting research and analysis on the implications of recent market trends on the dynamics between airports and airlines in Europe. Oxera found that the European aviation market grew by 25% between 2010 and 2016, with key trends including the continuing rapid expansion of LCCs (low-cost carriers) and non-traditional hubs in the Middle East and Istanbul. These developments have contributed to an intensification of the rivalry between airports, across all channels through which they compete. With many of these trends now being long established, the competitive pressures on airports, of all sizes, across Europe are highly likely to endure and continue to develop, implying that regulators and government stakeholders will need to address this ‘new normal’. Andrew Meaney, Partner and H
RHÖN-KLINIKUM AG Diligently Presses Ahead with Digitalization26.9.2017 18:29 | Tiedote
RHÖN-KLINIKUM AG is forging ahead with the implementation of its digitalization strategy and is launching a new collaboration with Austrian enterprise search and big data provider Mindbreeze, a subsidiary of the publicly listed Fabasoft AG. The clinic group will use Mindbreeze’s AI-based (artificial intelligence) search engine technology. With this application ─ in the form of a medical cockpit ─ that has been further developed in close cooperation with RHÖN-KLINIKUM AG, the entire medical staff can orient themselves more quickly and their workload is immediately alleviated. “This new approach to medical information will help us to structure the increasing amount of data and then make the information analyzable and evaluable. This is another aspect in which digitalization presents a tangible, concrete benefit,” says Stephan Holzinger, CEO of the group. The medical cockpit is initially being
Before the winter season, Mytyres.co.uk presents: Europe’s most popular summer tyres in 201726.9.2017 18:14 | Tiedote
In 2017, Europe’s most popular summer tyres were the Continental PremiumContact 6, the Uniroyal Rainsport 3, and the Dunlop SportMaxx RT2. This is the result of a survey conducted by Mytyres.co.uk, the end-user online shop for tyres, car spare parts and accessories from Europe's largest Internet tyre wholesaler Delticom. The survey was conducted throughout July and August in twelve European countries. Nearly 2,600 visitors to the online store cast their votes before the end of the summer tyre season. They were able to choose from five models by leading brands. “Interestingly, the results show that throughout Europe, high-quality premium brand models are the most popular”, comments Thierry Delesalle from Mytyres.co.uk. “These brands rightly enjoy a good reputation, but these days attractive alternatives are also available in the low-cost quality tyre segment. This also applies to
Quadient Launches Alliances and ISV/Technology Partner Tracks of Partner Advantage Program26.9.2017 17:30 | Tiedote
www.quadient.com : Quadient, formerly GMC Software, the award-winning leader in Customer Communications Management (CCM), announced today the launch of the Alliances Partner and ISV/Technology Partner tracks of its Partner Advantage Program intended to engage, empower and enable all types of Quadient partners. The two tracks complete the four-track program, which began with the announcement in April 2017 of the Delivery Partner track, designed to provide seamless implementation services for Quadient’s customer base. It was followed by the launch of the Business Partner track in May 2017, which offers technology service providers access to new revenue opportunities. Companies approved to become certified Alliances Partners are system integrators/consultants that deliver services, implement and support the Quadient solutions they recommend to their customers. ISV/Technolo
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme